Obesity and Metabolic Innovation Forum

As supply issues with Ozempic persist for Novo Nordisk, and Eli Lilly launch an unconventional but affordable single-dose version of Zepbound; there has never been a more crucial time to bring the obesity and metabolic health industry together.

Join us for this inaugural event where pharmaceutical companies, biotechs, payers, and providers come together to drive innovation, foster partnerships, and enhance access to effective obesity and metabolic health treatments. With a sharp focus on GLP-1s, we will explore the business dynamics behind this ground-breaking modality and its significant impact on the health industry.

Our conference features insights from top companies and thought leaders, tackling the most pressing issues and trends in obesity and metabolic health, including:

- Transforming Obesity and Metabolic Health
- Market Access and Cost Containment
- Expanding the Therapeutic Horizons of GLP-1 Drugs
- Regulatory Challenges

Why attend?

Gain Strategic Expertise:
Deepen your understanding of regulatory and reimbursement landscapes with insights from industry leaders like Novo Nordisk, Sanofi, BCBS, and Cigna.

Access Exclusive Innovations:
Discover new indications, delivery methods, and beyond-the-pill strategies from startups and innovators, while learning what's attracting investor interest.

Unmatched Networking:
Connect with top decision-makers in obesity and cardiometabolic health, build strategic partnerships, secure investment opportunities, and advance your organization's solutions.

Don't miss your chance to be at the cutting edge of GLP-1 innovation and industry transformation.

Quote 'EVNNT10' to claim 10% off your registration.

We look forward to seeing you in Boston!

URL:
Tickets: https://go.evvnt.com/2674209-0?pid=10018

Prices:
Tier 1 - Academics / Research Institutes / Healthcare Providers / Clinicians: USD 1399.00,
Tier 2 - Start Ups (Biotech and Tech) - Pre-Series A Funding: USD 2099.00,
Tier 3 - Pharma and Biotechs / Investors / Regulators: USD 2399.00,
Tier 4 - Service Providers - Vendors and Consumer / Fitness / CDMO / CROs / Consultants / Research Tools: USD 3499.00

Speakers: Ulrik Brandt, Global Associate Director, NOVO NORDISK, Robert Gabbay Chie,f Science and Medical Officer, AMERICAN DIABETES ASSOCIATION, Soanli Malhotra, Global Development Medical Director, ASTRAZENECA, Philip Larsen, CEO, SIXPEAKS BIO, Disha Narang, Director of Obesity Medicine, ENDEAVOUR HEALTH